Fluidigm

Fluidigm

South San Francisco, California, United States
South San Francisco United States
Employees:
590
Market Cap:
$178.12 million
Revenue:
$104.23 million
5 Year Trend:
19.5%
Net Income:
$-74.52 million
NASDAQ:
FLDM
Industry:
Computer and Electronic Product Manufacturing
Founded:
1999

Fluidigm Corporation is a public, American company engaged in the design, manufacture and sale of biological research equipment based on integrated fluidic circuit technology. In 2009, Fluidigm was described as "the worlds leading manufacturer of microfluidic devices." Among the applications to which Fluidigm products are put to use are protein crystallization, genotyping, DNA analysis and PCR. Wikipedia

Fluidigm

South San Francisco, California, United States
South San Francisco United States

Fluidigm Corporation is a public, American company engaged in the design, manufacture and sale of biological research equipment based on integrated fluidic circuit technology. In 2009, Fluidigm was described as "the worlds leading manufacturer of microfluidic devices." Among the applications to which Fluidigm products are put to use are protein crystallization, genotyping, DNA analysis and PCR. Wikipedia

Employees:
590
Market Cap:
$178.12 million
Revenue:
$104.23 million
5 Year Trend:
19.5%
Net Income:
$-74.52 million
NASDAQ:
FLDM
Industry:
Computer and Electronic Product Manufacturing
Founded:
1999
  • Oct 31 at 10:00 PM
    Bernd Bodenmiller, PhD, Assistant Professor at the University of Zurich and key innovator in the field of Imaging Mass Cytometry shares his thoughts on this exciting new application in the context of cancer research. "Because we are interested in the tumor ecosystem, an approach like Imaging Mass Cytometry is an absolute necessity to reveal the level of information that includes cell type identity, the functional state of individual cells and the spatial relationships of those cells, said Dr. Bodenmiller. Hear Dr. Bodenmiller speak about his research at the Fluidigm Hyperion Imaging System announcement event held on October 24, 2017. http://ow.ly/yNSs30gd3VE
  • Oct 30 at 10:00 PM
    What's so exciting about the Hyperion Imaging System? It significantly expands the number of protein markers that researchers can simultaneously detect in tumors and tissues by an application called Imaging Mass Cytometry. By providing unprecedented visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology, and immune-mediated diseases, it has the potential to revolutionize disease research and empower the development of better diagnostics and more effective therapies in the future. Learn more http://ow.ly/RFOB30gd22d
  • Oct 24 at 7:50 PM
    Video: If you missed the Imaging Mass Cytometry (IMC) announcement program today, you can now see it online. Chris Linthwaite, CEO of Fluidigm, opened the program by introducing the Hyperion Imaging System. Leading researchers then shared insightful presentations on how IMC can be used to enable a greater understanding of complex cellular phenotypes and their relationships in the context of the tissue microenvironment, tumor immunity and CTC characterization. Presenters: Chris Linthwaite, CEO, Fluidigm Bernd Bodenmiller, PhD, University of Zurich Matt Silver, PhD, EMD Serono Akil Merchant, MD, University of Southern California Watch it at http://ow.ly/Qa7c30g6sGd
  • Oct 24 at 2:14 PM
    Just announced: Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues. Watch the announcement event program today with presentations by Chris Linthwaite, CEO of Fluidigm, and leading researchers using Imaging Mass Cytometry. http://ow.ly/bo0a30g5U3l

Oct 31, 10:00 PM

Bernd Bodenmiller, PhD, Assistant Professor at the University of Zurich and key innovator in the field of Imaging Mass Cytometry shares his thoughts on this exciting new application in the context of cancer research. "Because we are interested in the tumor ecosystem, an approach like Imaging Mass Cytometry is an absolute necessity to reveal the level of information that includes cell type identity, the functional state of individual cells and the spatial relationships of those cells, said Dr. Bodenmiller. Hear Dr. Bodenmiller speak about his research at the Fluidigm Hyperion Imaging System announcement event held on October 24, 2017. http://ow.ly/yNSs30gd3VE

Oct 30, 10:00 PM

What's so exciting about the Hyperion Imaging System? It significantly expands the number of protein markers that researchers can simultaneously detect in tumors and tissues by an application called Imaging Mass Cytometry. By providing unprecedented visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology, and immune-mediated diseases, it has the potential to revolutionize disease research and empower the development of better diagnostics and more effective therapies in the future. Learn more http://ow.ly/RFOB30gd22d

Oct 24, 7:50 PM

Video: If you missed the Imaging Mass Cytometry (IMC) announcement program today, you can now see it online. Chris Linthwaite, CEO of Fluidigm, opened the program by introducing the Hyperion Imaging System. Leading researchers then shared insightful presentations on how IMC can be used to enable a greater understanding of complex cellular phenotypes and their relationships in the context of the tissue microenvironment, tumor immunity and CTC characterization. Presenters: Chris Linthwaite, CEO, Fluidigm Bernd Bodenmiller, PhD, University of Zurich Matt Silver, PhD, EMD Serono Akil Merchant, MD, University of Southern California Watch it at http://ow.ly/Qa7c30g6sGd

Oct 24, 2:14 PM

Just announced: Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues. Watch the announcement event program today with presentations by Chris Linthwaite, CEO of Fluidigm, and leading researchers using Imaging Mass Cytometry. http://ow.ly/bo0a30g5U3l